

36. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass
- a. a therapeutically effective amount of a first compound, said first compound being droloxifene, raloxifene, tamoxifen or idoxifene; and
  - b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride.

Please cancel claims 43 and 44 without prejudice or disclaimer.

Please amend claims 45 and 46 as follows:

45. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:
- a. a therapeutically effective amount of droloxifene, raloxifene, tamoxifen or idoxifene and a pharmaceutically acceptable carrier in a first unit dosage form;
  - b. a therapeutically effective amount of a sodium fluoride and a pharmaceutically acceptable carrier in a second unit dosage form; and
  - c. container means for containing said first and second dosage forms.
46. (Amended) A pharmaceutical composition comprising:
- a. a therapeutically effective amount of a first compound, said first compound being

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
naphthalene-2-ol;

(-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-  
naphthalene-2-ol;

Cis-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-  
tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-  
tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-  
tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-  
tetrahydroisoquinoline; and

- b. a therapeutically effective amount of a second compound, said second compound  
being sodium fluoride, a parathyroid hormone, or growth hormone.

Please cancel claim 51 without prejudice or disclaimer.

Please amend claim 52 as follows:

52. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

a. a therapeutically effective amount of a first compound, said first compound being

Cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

(-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;

Cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;

1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;

Cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and

- b. a therapeutically effective amount of a second compound, said second compound being sodium fluoride, a parathyroid hormone, or growth hormone.

Please cancel claims 56, 63, and 64 without prejudice or disclaimer.

Please amend claims 65 and 73 as follows:

65. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:
- a. a therapeutically effective amount of
- Cis*-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- (-)-*Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- Cis*-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
- Cis*-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydrohaphthalene;
- 1-(4'-Pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;
- Cis*-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol; or

1-(4'-Pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline  
and a pharmaceutically acceptable carrier in a first unit dosage form;

- b. a therapeutically effective amount of sodium fluoride, a parathyroid hormone, or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and
- c. container means for containing said first and second dosage forms.

73. (Amended) A pharmaceutical composition comprising:

- a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and
- b. a therapeutically effective amount of a second compound, said second compound being a parathyroid hormone or growth hormone.

Please cancel claim 78 without prejudice or disclaimer.

Please amend claim 79 as follows:

79. (Amended) A method for treating a mammal having a condition which presents with low bone mass comprising administering to a mammal having a condition which presents with low bone mass

- a. a therapeutically effective amount of a first compound, said first compound being raloxifene, tamoxifen or idoxifene; and
- b. a therapeutically effective amount of a second compound, said second compound

being a parathyroid hormone or growth hormone.

Please cancel claims 83, 90, and 91 without prejudice or disclaimer.

92. (Amended) A kit containing a treatment for a condition which presents with low bone mass comprising:

- a. a therapeutically effective amount of raloxifene, tamoxifen or idoxifene; and a pharmaceutically acceptable carrier in a first unit dosage form;
- b. a therapeutically effective amount of a parathyroid hormone or growth hormone and a pharmaceutically acceptable carrier in a second unit dosage form; and
- c. container means for containing said first and second dosage forms.

Please add new claims 93-108, as follows:

93. (New) A combination that comprises an estrogen agonist/antagonist and a growth hormone secretagogue. ✓
94. (New) The combination of claim 93, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt. ○
95. (New) The combination of claim 93, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof. ✓
96. (New) The combination of claim 93, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof. ○

97. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 93. ✓
98. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 94. ○
99. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 95. ✓
100. (New) A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 96. ○
101. (New) The method of claim 97 wherein the condition is osteoporosis. ✓
102. (New) A pharmaceutical composition comprising an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier. ✓
- 103. (New) The composition of claim 102, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt. ○
104. (New) The composition of claim 102, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof. ✓

105. (New) The composition of claim 102, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof. (D)
106. (New) A process for making a pharmaceutical composition comprising combining an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier. ✓
107. (New) The process of claim 106, wherein the estrogen agonist/antagonist is raloxifene, (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof. J
108. (New) The process of claim 106, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt. O